If you wish to ask a question on today's call, please press star one. Please press star on your phone followed by one. That's star 1 if you wish to ask a question. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note this conference is being recorded. I will now turn the conference over to your host, Callon Nichols, Director of Investor Relations at Sanara MedTech. Callon, you may begin. Thank you, and good morning, everyone. I'd like to welcome you to Sanara MedTech's earnings conference call for the quarter ended March 31st, 2024. We issued our earnings release yesterday morning, and I would like to highlight that we have posted today's deck on the Investor Relations page of our website. This supplemental deck, as well as a copy of the earnings release and the Form 10-Q for the quarter ended March 31st, 2024, are also available on this page. We will reference this information in our remarks today. With us today are Ron Nixon, our Executive Chairman and CEO, Mike McNeil, our Chief Financial Officer, and Seth Yon, our President Commercial. Please note that certain statements in this conference call, in our press release, and in our supplemental deck include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For more information about the risks and uncertainties involving forward-looking statements and factors that could cause actual results to differ materially from those projected or implied by forward-looking statements, please see the risk factors set forth in our most recent annual report on Form 10-K, as supplemented by the risk factors in our most recent quarterly report on Form 10-Q. Also, this conference call, our earnings release, and supplemental deck reference certain non-GAAP measures. In that regard, I direct you to the reconciliation of these measures in the earnings materials that are available on our website. Now I'd like to turn the call over to Ron. Thank you, Callon, and good morning, everyone. As we mentioned in our press release yesterday, our former CEO, Zach Fleming, resigned on Friday. We're in the process of finalizing a separation agreement with Zach, and I've been appointed CEO by the company's board of directors. As a result of Zach's departure, the company will no longer be presenting the proposal for the election of a ninth director on our board of directors at the annual meeting of shareholders in June. As many of you know, I've been intimately involved with the leadership team in developing and executing Sanara's strategic vision since the inception of Sanara MedTech, and I'm looking forward to working with the Sanara's leadership team now on a daily basis to continue that execution. Turning to our first quarter results, first quarter of 2024 was the company's 10th consecutive record quarter. The company generated $18.5 million in revenue in Q1 over the course of 2023. 2023, we made significant advancements in data analytics, sales force optimization, and sales processes. As I've told many of you before, when you're in a high-growth business, you need to be able to build infrastructure, data analytics, and details around these processes in order to be able to improve to continue that growth. We believe that that's been implemented, and that will pay dividends going forward. These improvements and the momentum we've achieved in the fourth quarter helped us to exceed our forecast for the first quarter, and we believe position us to continue to build upon the success the team's achieved in previous periods. For the three months ended March 31st, 2024, the company had a Net Loss of $1.8 million, while we generated positive Adjusted EBITDA of $300,000 over the same period. I'd like to provide a brief update on our partnership with InfuSystem. We continue to invest in this partnership and are focused on three potential areas of opportunity. The first initiative for the partnership is to distribute Sanara's advanced wound care products, including BIAKŌS and HYCOL, as well as negative pressure wound therapy products into long-term care, skilled nursing facilities, and wound centers. Building upon these strategic objectives, we're also exploring emerging opportunities for InfuSystem to distribute our advanced wound care products outside of this channel. We also believe that our partnership will play a key role in Tissue Health Plus, our value-based care strategy that you've heard about many times before, which is planned to include standardized wound prevention and treatment plans that utilize Sanara's wound care products. As these opportunities continue to develop, we will provide additional updates. As I mentioned in our last call, we're having discussions with potential partners participating in the execution of the Tissue Health Plus strategy. During the process, we're continuing to invest in the technology, capabilities, and infrastructure that we believe are required to commercialize this very well-designed strategy. But we do not anticipate that this will continue spending by us alone in 2024, and we hope to have our partnerships in place so that we can execute. These partners we're looking for are not just financial partners. They are strategic partners. We're also continuing focusing expansion of the existing surgical product offering. Lastly, we made significant progress in the area of intellectual property and manufacturing processes for Cellerate product line itself. We think that this has been something we've talked about for many times, and we believe that it's got a significant ability for us to be able to get more IP around the product as we continue to advance this through many of the different specialties. I'd like to now introduce you to Seth Yon, our President of Commercial. Seth has been with the company since 2018 and, over the years, has been promoted multiple times to roles of increasing responsibility. In his current position as President of Commercial, he leads our national sales team and multiple internal teams, including marketing, customer support, national accounts, and business operations. He's been instrumental in building out our sales team and infrastructure at Sanara, and I look forward to working closely with him on the execution of our strategy. Seth, I'll now turn it over to you to discuss our surgical sales results in more detail. Thanks, Ron. In the first quarter of 2024, our products were sold in over 1,082 facilities across 34 states and the District of Columbia. We continue to focus on increasing the use of our products in new and existing territories, expanding usage into new specialties, and increasing our per-facility sales. Our products were approved to be sold in more than 3,000 facilities as of March 31st, 2024. Subsequent to the end of the quarter, a new contract with a large GPO went into effect, which has had a significant impact on the number of facilities in which our products are approved to be sold. Sales of our soft tissue products grew from $12.9 million in the first quarter of 2023 to $16.1 million in the first quarter of 2024. Sales of bone fusion products decreased slightly from $2.6 million in 2023 to $2.5 million in 2024. This was due to a slower-than-expected adoption of ALLOCYTE Plus, as well as a larger-than-normal order from a facility in Q1 of 2023 of BiFORM, which subsequently returned to previous levels in subsequent quarters. I will now turn it over to Mike McNeil to discuss the details of our recent loan agreement with CRG, as well as our most recent financial results. Mike? Thank you, Seth. I'd like to discuss the new debt facility we recently announced with CRG. This transaction helped us strengthen our cash position and provided access to growth and acquisition capital in a way that was non-dilutive to equity holders. The facility allows for flexibility in the event of a transaction we believe would be accretive, given the fact the company has the ability to draw additional capital beyond the initial $15 million at our option. We are currently in discussions with the commercial bank for an additional $10 million revolver as permitted under the CRG facility, which could give us access to what we expect will be lower-cost capital for any immediate needs. The term loan is structured as a senior secured loan with a five-year term and up to $55 million in aggregate potential proceeds. In addition to the $15 million drawn at close, we can draw up to an additional $40 million before June 30, 2025. I'll now go into more detail about our most recent financial results for the three months ended March 31st, 2024. Sanara generated net revenue of $18.5 million compared to $15.5 million for the first quarter of 2023, a 19% increase over the prior year period. The higher revenue in 2024 was due to increased sales of our soft tissue repair products, including CellerateRX, as a result of increased market penetration, geographic expansion, and our continuing strategy to expand independent distribution network in both new and existing U.S. markets. SG&A expenses for the first quarter of 2024 were $16.2 million compared to $13 million for the same period in 2023. The higher SG&A expenses in the first quarter of 2024 were primarily due to higher direct sales and marketing expenses, which accounted for approximately $2.2 million or 69% of the increase compared to the prior year period. The higher direct sales and marketing expenses were primarily attributable to an increase in sales commissions of $1.6 million as a result of higher product sales and $0.6 million of increased costs as a result of sales force expansion and operational support. R&D expenses for the three months ended March 31st were $0.9 million compared to $1.3 million for the same period in 2023. The lower R&D expenses in 2024 were primarily due to lower costs associated with the Precision Healing Diagnostic Imager and LFA. Sanara had a first-quarter net loss of $1.8 million compared to a net loss of $1.2 million during the same period in 2023. The higher net loss in 2024 was due to higher SG&A costs and higher amortization of our acquired intangible assets, partially offset by higher gross profit and lower R&D expenses. Our cash on hand at the end of the quarter was $2.8 million. With that, I'll turn it back to Ron for some closing remarks. Thanks, Mike. We're pleased with our progress in the first quarter, continued growth, and the results that we had in that first quarter. We obviously are striving to seek profitability. This is not a revenue play. This is a play to build a business and build it for the long term, and we plan to do so. Related to our surgical business, we've had multiple opportunities that we continue to review that complement our existing product offering. We continue to expand our products into other areas of specialty as well as other hospitals. You know how many hospitals we're in today, and we want to continue to advance that across the U.S. This concludes our remarks, and we look forward to answering any questions you may have. Operator, we're ready to open the calls for questions. Thank you. At this time, we'll be conducting a question-and-answer session. If you would like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star two if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. Once again, please press star one on your phone at this time if you wish to ask a question, and please hold while we pull for questions. And once again, that will be a star one on your phone if you wish to ask a question. And we did have a question come in from Ian Cassel from IFCM. Ian, your line is live. Yeah, Ron, it's that one question, and I could jump back in the queue. My question was, the recent CEO transition, has that transition disrupted the sales momentum you've shown through Q1? Not at all. I would tell you, Ian, that the team is stronger than it's ever been. Seth Yon has been driving this for a long period of time, and the sales team is, we're sorry to see him go, but quite frankly, there's zero disruption. Okay. I'm going to do a follow-up question, maybe for Seth. I noticed that the bone fusion products, they've been kind of flat year-over-year. I was wondering if you could maybe speak to that since I believe the supply disruption kind of became abated in Q4. Sure. As I mentioned earlier, we did have a little bit of softening as we returned with ALLOCYTE Plus, and I do believe a lot of that is related to timing. As you can imagine, when you have an issue with inventory, that inventory then becomes an issue, and it's replaced at a facility level with something else. And so we've had to start that cycle, that process again, to get that product back in and get re-engaged with our distributors as well. And that cycle, that process has taken a little bit longer than we had expected. Thank you. Thank you. There were no other questions from the lines at this time. Once again, if you do have a question, please press star one on your phone. That's star one if you wish to ask a question today. Okay, we did have Ian Cassel come in with a follow-up. Ian, your line is live. When we think about the Tissue Health Plus and partnering on that, is that and I was trying to remember what you said in your prepared remarks, but is that something that you expect, hopefully, to happen by the end of 2024, being able to have some partnerships for that? Yes, it is what we anticipate. So, Ian, what we have done is we have designed a really thoroughly thought-out strategy for how you approach value-based in wound care. And actually, no one has ever actually done this, so it is complicated because you've got payers, you've got providers, you've got products, you've got patients traveling through the continuum. So there's the issue of where do you take care of these patients? Because they're in the home setting, they're in home care, they're in SNFs, they're in LTACs. And because of all the discussions we've had historically about how episodic care does not fit well with the wound just from a timing standpoint, typically, the focus is on the primary comorbidity that gave rise to that wound. And so you really have to think through, how do we catch this in its journey? How do we build a platform that will allow for us to have continuous monitoring of that patient, but also have care coordination and navigation to be able to work through this? So when you think of all those steps, those are ideal partners that we would look for to participate with us, and that would be a financial partner as well as a partner that brings some value-add to our overall strategy. Okay. Maybe a follow-up. You're now CEO of the company. Do you view this as a temporary thing, or do you see yourself staying in here permanently? It was a temporary thing when I started and spent two and a half years in the seat. I'm actually in the seat every day, and there's not a day goes by that I'm not talking to somebody from Sanara. Really, from my perspective, it's just a better line of communication from me to everyone. We're going to just onward and upward, and I'm looking forward to the journey, and I have no plans to change out of this position anytime soon unless something unforeseeable happens. So I'm trying to dodge as many cars as I can, etc. If something doesn't happen, but I'm looking forward to it. This is my passion. This was originally my concept of what we wanted to go do and build this business, and I think we've done a remarkable job, and it's only from one thing. It's not me. It's because we have people that are highly competent, that are passionate about what we do, and they are in our company. I don't see anybody that doesn't have that passion continuing and going forward for the execution of our strategy. And maybe to that, you recently announced adding two more folks to the management team. Can you talk about why you brought them on board and your experience working with them? Yes. Absolutely. We have a great team to begin with, but what you have to do is you're going through these growths, and we're anticipating higher growth. So when you anticipate higher growth, you have to have more people in the seat. And we look at a lot of opportunities, so we felt like we needed a dedicated corporate development person that also has got a strategic background. And so that's Tyler Palmer that joined us. He's got a longstanding experience in wound care. And then we also need that operational focus with somebody that's also got financial strengths to complement what we do. And that's Jake Waldrop. And Jake and I have worked together for many years, and he came out of the ortho business in the lower extremity ortho space, and he understands it really well. And he is a former chief financial officer that adapted real well to being a chief operating officer. So we are delighted to have both of those in our camp. But what we also don't talk about is just all the other new people that come on to support all of this in our sales effort, the new trainees that come on board from the sales side. That all are just remarkable, and we're excited about coming on because we just keep getting more laser-focused on what our needs are. And with those needs, we go identify the right kind of people. And if you've got a good strategy in a growth company, people that are high performers seek you out. And so I'm very positive about where we're going, and I feel very good about the depth of the team. And this is not stopping. We'll continue to advance the depth of the team in order to keep up always with the infrastructure. As I've always said, companies go up. They've got to go sideways to build infrastructure and support so that they don't collapse. Then they go back up again. It's a journey, and it just continues to happen, and that's how you can build greatness. Okay. Thanks, Ron. Thank you, Ian. Thank you. And once again, if you do have a question today, please press star one on your phone. That's star one if you wish to ask a question today. And while we wait for any other questions, we did have a couple come in from the web. And can you speak to the profitability in relation to the revenue increasing or indeed decreasing, but the profitability taking a step back? And then also, can you share some color around the SG&A increase and how it appears to be increasing as fast or faster than the revenue quarter-over-quarter? Yeah. So I will start by speaking to the lumpiness of how costs come in, and that is depending on how we're hiring, depending on how we are advancing sales. As you know, on our SG&A, a big variable in the SG&A is commissions paid. That correlates very well with more sales coming in. And Mike, I'll let you talk about it in just a second, but as you think about the business, we are striving for profitability. We've achieved profitability, although in a minor way. That's not where we want our levels to be. But what we also have to balance is that when we see opportunities that we think are a really good opportunity for our shareholders long-term in building value, we want to be prudent and make sure that we've got adequate capital, that if we're going to take a bet on something that we believe will add significant value to us, we just need to make sure that we have a level of cash available to us to be able to do that, which means that we might forego some period of time for profitability if we know it's going to be a multiple of that from the investment that we made. But operational efficiency, sales efficiency, and profitability are all top of mind. Mike, is there anything else you'd like to add to that? Yeah. Yeah, thanks, Ron. I would just like to add 2023 included a couple of benefits to the P&L, such as change in fair value of earnout liabilities. We had a big credit last year that we didn't have this year. And then also, the amortization of our intangibles went up significantly, and that really accounts for the higher net loss in 2024. Thank you, Mike. Okay. There were no other questions in queue at this time. I would now like to hand the call back to Ron Nixon for closing remarks. Okay. Thank you very much. We thank all our shareholders for being on the call today. It is, besides the people in our firm, the shareholders matter a lot. We love the continued support that you've given us, and thank you very much for the support through this transition. As we said, we do not believe it will be disruptive at all, but many of you have called to talk about your confidence with our firm, and we thank you for that and greatly appreciate it. Thank you very much, and we look forward to talking to our shareholders in the near term. Take care. Thank you. This does conclude today's conference. You may disconnect your lines at this time. Thank you for your participation.